StemCell Therapy

Magellan Stem Cells has welcomed a $7 million grant from the federal governments Medical Research Future Fund (MRFF) to help fund a Phase 3 human trial of the companys donor stem cell treatment for osteoarthritis.

In announcing the grant, Health Minister Mark Butler said, We are living through a supercharged period of discovery in health and medical research, and the Albanese Government is proud to support Australias world class researchers.

Stem cell therapies could provide innovative treatments for many chronic and inherited diseases we cant yet treat effectively. Such therapies could also revolutionise how we test and develop new medications."

Magellans Phase 3 osteoarthritis trial is one of six projects sharing $34.5 million supported by the MRFF Stem Cell Therapies Research Grant Opportunity.

Osteoarthritis is a huge cause of pain and disability in Australia, said Minister Butler. Up until now the treatments only extended to pain relief and potentially replacement surgery, like knee replacements.

The trial of Magellans donor stem cell treatment for osteoarthritis is scheduled to begin next year.

The grant was announced following the publication of research by Magellan, which demonstrated the potential for significant therapeutic benefits of its MAG200, an off-the-shelf donor stem cell therapy for osteoarthritis.

The research findings are published in Osteoarthritis and Cartilage Open.

Lead researcher and Magellan chief medical officer, Associate Professor Julien Freitag, said, We are very grateful to the Australian Government and the

Medical Research Future Fund (MRFF) for their support for this potentially life-changing technology.

The grant is a vote of confidence in the future of the Australian biotech sector, stem cell technology and Magellans ground-breaking research.

View post:
Magellan Stem Cells welcomes $7 million federal government grant

Tags:

This entry was posted on September 21, 2024 at 2:38 am and is filed under Stem Cell Therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |